胆固醇代谢酶CYP46A1及其代谢物24S-羟基胆固醇在缺血性卒中中的作用
研究探讨胆固醇代谢酶CYP46A1及其代谢物24S-羟基胆固醇(24S-HC)在缺血性脑损伤中的作用。电生理、药理学和转基因方法及体内外脑缺血模型显示,24S-HC以浓度依赖性方式增强NMDAR激活,10 µmol/L时稳态电流增加51%、峰电流增加20%,并加重NMDA和氧糖剥夺诱导的皮质神经元损伤;该损伤可被NMDAR通道阻滞剂MK-801大部分消除。伏立康唑抑制CYP46A1或Cyp46a1基因敲除可显著减轻缺血性脑损伤。
要点
- 24S-HC以浓度依赖性方式增强小鼠皮质神经元NMDAR激活,10 µmol/L时稳态电流增加51%、峰电流增加20%。
- 24S-HC加重NMDA和氧糖剥夺诱导的皮质神经元损伤,该损伤可被MK-801大部分消除,提示NMDAR依赖机制。
- 伏立康唑抑制CYP46A1或Cyp46a1基因敲除可显著减轻缺血性脑损伤。
核心结论
- CYP46A1→24S-HC→NMDAR→缺血性脑损伤是影响卒中结局的新机制和信号级联,为靶向CYP46A1或其代谢物24S-HC的卒中干预策略提供原理验证。
研究设计与样本
- 采用电生理、药理学和转基因方法,在体外和体内脑缺血模型中验证假说。
主要发现
- 24S-HC在10 µmol/L时使原代培养小鼠皮质神经元稳态电流增加51%、峰电流增加20%。
- 24S-HC加重NMDA和氧糖剥夺诱导的皮质神经元损伤,该损伤可被NMDAR通道阻滞剂MK-801大部分消除。
- 伏立康唑抑制CYP46A1或Cyp46a1基因敲除可显著减轻缺血性脑损伤。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For several decades, it has been recognized that overactivation of the glutamate-gated N-methyl-D-aspartate receptors (NMDARs) and subsequent Ca2+ toxicity play a critical role in ischemic brain injury. 24S-hydroxycholesterol (24S-HC) is a major cholesterol metabolite in the brain, which has been identified as a potent positive allosteric modulator of NMDAR in rat hippocampal neurons. We hypothesize that 24S-HC worsens ischemic brain injury via its potentiation of the NMDAR, and reducing the production of 24S-HC by targeting its synthetic enzyme CYP46A1 provides neuroprotection. METHODS: We tested this hypothesis using electrophysiological, pharmacological, and transgenic approaches and in vitro and in vivo cerebral ischemia models. RESULTS: Our data show that 24S-HC potentiates NMDAR activation in primary cultured mouse cortical neurons in a concentration-dependent manner. At 10 µmol/L, it dramatically increases the steady-state currents by 51% and slightly increases the peak currents by 20%. Furthermore, 24S-HC increases NMDA and oxygen-glucose deprivation-induced cortical neuronal injury. The increased neuronal injury is largely abolished by NMDAR channel blocker MK-801, suggesting an NMDAR-dependent mechanism. Pharmacological inhibition of CYP46A1 by voriconazole or gene knockout of Cyp46a1 dramatically reduces ischemic brain injury. CONCLUSIONS: These results identify a new mechanism and signaling cascade that critically impacts stroke outcome: CYP46A1 → 24S-HC → NMDAR → ischemic brain injury. They offer proof of principle for further development of new strategies for stroke intervention by targeting CYP46A1 or its metabolite 24S-HC.
引用
- Sun H, Yang T, Simon RP, et al. Role of Cholesterol Metabolic Enzyme CYP46A1 and Its Metabolite 24S-Hydroxycholesterol in Ischemic Stroke. Stroke. 2024. PMID: 39224978. doi:10.1161/STROKEAHA.124.047803
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。